Takeda Pharmaceutical Co. (NYSE:TAK) Shares Acquired by Avantax Advisory Services Inc.

Key Points

• Avantax Advisory Services Inc. significantly increased its holdings in Takeda Pharmaceutical Co. by 941.6%, owning 114,298 shares worth $1.7 million as of their latest SEC filing.
• Takeda Pharmaceutical reported earnings per share (EPS) of $0.16 for the most recent quarter, which fell short of analyst expectations of $0.24, while revenue was $7.34 billion against a forecast of $8.02 billion.
• The company's current stock price is at $13.73, with a market capitalization of $43.67 billion and a P/E ratio of 45.75.

Avantax Advisory Services Inc. grew its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 941.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,298 shares of the company's stock after purchasing an additional 103,325 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Takeda Pharmaceutical were worth $1,700,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. First Trust Advisors LP raised its stake in shares of Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock worth $42,910,000 after buying an additional 62,718 shares during the last quarter. Northern Trust Corp grew its holdings in Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after buying an additional 238,161 shares during the period. Soleus Capital Management L.P. grew its holdings in shares of Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock worth $15,623,000 after purchasing an additional 680,000 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth about $6,760,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Takeda Pharmaceutical by 15,449.0% during the 4th quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock worth $6,629,000 after purchasing an additional 497,457 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 0.3%

NYSE TAK traded up $0.05 on Monday, reaching $14.21. The company had a trading volume of 3,937,836 shares, compared to its average volume of 2,441,136. The firm has a market capitalization of $45.20 billion, a PE ratio of 47.35 and a beta of 0.22. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.53. The firm has a 50-day moving average of $14.86 and a 200-day moving average of $14.53. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. On average, equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.